Cadila Healthcare Limited has informed the Exchange regarding a press release dated October 08, 2021, titled "Fortress Biotech and Cyprium Therapeutics with support from its licensing partner Sentynl Therapeutics, Inc. a wholly owned subsidiary of Cadila Healthcare Limited ( Zydus ) Announce Positive Clinical Data for CUTX-101, Copper Histidinate for the treatment of Menkes Disease".
Press Release Oct 08 2021
Filed with NSE · · 6 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 24 2021
- Press Release Sep 18 2021
- Press Release Sep 09 2021
- Press Release Sep 06 2021
- Press Release Aug 23 2021
Later from Zydus Lifesciences
- Press Release Oct 22 2021
- Press Release Nov 08 2021
- Press Release Nov 10 2021
- Press Release Nov 12 2021
- Press Release Nov 18 2021
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences